The effect of a single dose of oral ivermectin on pruritus in the homeless

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 2, 2008, Pages 404-409

  Badiaga, Sékéné ^a,b   Foucault, Cédric ^a,c   Rogier, Christophe ^d   Doudier, Barbara ^c   Rovery, Clarisse ^a,c   Dupont, Hervé Tissot ^c   Castro, Pierre ^b   Raoult, Didier ^a,c   Brouqui, Philippe ^a,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL NORD   (France)

^c Laboratoire de Virologie Pôle hospitalier de Microbiologie et Maladies Infectieuses   (France)

^d SERVICE DE SANTÉ DES ARMÉES   (France)

Author keywords

Body louse; Clinical trial; Infection control; Scabies; Skin infection

Indexed keywords

IVERMECTIN; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; ECTOPARASITE; FOLLOW UP; FRANCE; HOMELESSNESS; HUMAN; MAJOR CLINICAL STUDY; MALE; PEDICULOSIS; PREVALENCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SINGLE DRUG DOSE; SKIN INFECTION;

ADMINISTRATION, ORAL; ADULT; ANIMALS; DOUBLE-BLIND METHOD; FRANCE; HOMELESS PERSONS; HUMANS; INSECTICIDES; IVERMECTIN; LICE INFESTATIONS; MIDDLE AGED; PEDICULUS; PLACEBOS; PRURITUS;

EID: 47249091919     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn161     Document Type: Article

References (15)

1. Brouqui P, Stein A, Tissot Dupont H et al. Ectoparasitism and vector-borne diseases in 930 homeless people from Marseilles. Medicine 2005; 84: 1-8.
2. Badiaga S, Menard A, Tissot Dupont H et al. Prevalence of skin infections in sheltered homeless. Eur J Dermatol 2005; 15: 382-6.
3. Raoult D, Foucault C, Brouqui P. Infections in the homeless. Lancet Infect Dis 2001; 1: 77-84.
4. Brouqui P, Raoult D. Arthropod-borne diseases in homeless. Ann N Y Acad Sci 2006; 1078: 223-35.
5. Chosidow O. Scabies. N Eng J Med 2006; 354: 1718-27.
6. Raoult D, Roux V. The body louse as a vector of re-emerging human diseases. Clin Infect Dis 1999; 29: 453-8.
7. Fox LM. Ivermectin: Uses and impact 20 years on. Curr Opin Infect Dis 2006; 19: 588-93.
8. Bell TA. Treatment of Pediculis humanus var. capitis infestation in Cowlitz County, Washington, with ivermectin and the LiceMeister comb. Pediatr Infect Dis 1998; 17: 923-4.
9. Mumcuoglu KY, Miller J, Rosen JL et al. Systemic activity of ivermectin on the human body louse (Anoplura: Pediculidae). J Med Entomol 1990; 27: 72-5.
10. Foucault C, Ranque S, Badiaga S et al. Oral ivermectin in the treatment of body louse. J Infect Dis 2006; 193: 474-6.
11. Currie BJ, Hamural P, McKinnon M et al. First documentation of in vivo and in vitro resistance in Sarcoptes scabiei. Clin Infect Dis 2004; 39: E8-12.
12. Burkhart CG, Burkhart CN. Head lice therapies revisited. Dermatol Online J 2006; 12: 3.
13. Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet 1997; 349: 1144-5.
14. Del Giudice P, Marty P, Gary-Toussaint M et al. Ivermectin in elderly patients. Arch Dermatol 1999; 135: 351-2.
15. Elgart GW, Meinking TL. Ivermectin. Dermatol Clin 2003; 21: 277-82.